Upadacitinib effective in treatment of ankylosing spondylitis pts refractory to biologic tx - phase 3 trial Primary endpoint (ASAS40) and secondary endpoints met No malignancy, MACE, VTE, death @RheumNow #EULAR2022 ABST#POS0306 https://t.co/UL4hUJ0rQV